| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Microbiology and Immunology and
Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461
The Ag receptor of cytotoxic CD8+ T lymphocytes recognizes peptides of 8–10 aa bound to MHC class I molecules. This Ag recognition event leads to the activation of the CD8+ lymphocyte and subsequent lysis of the target cell. Altered peptide ligands are analogues derived from the original antigenic peptide that commonly carry amino acid substitutions at TCR contact residues. TCR engagement by these altered peptide ligands usually impairs normal T cell function. Some of these altered peptide ligands (antagonists) are able to specifically antagonize and inhibit T cell activation induced by the wild-type antigenic peptide. Despite significant advances made in understanding TCR antagonism, the molecular interactions between the TCR and the MHC/peptide complex responsible for the inhibitory activity of antagonist peptides remain elusive. To approach this question, we have identified altered peptide ligands derived from the vesicular stomatitis virus peptide (RGYVYQGL) that specifically antagonize an H-2Kb/vesicular stomatitis virus-specific TCR. Furthermore, by site-directed mutagenesis, we altered single amino acid residues of the complementarity-determining region 3 of the ß-chain of this TCR and tested the effect of these point mutations on Ag recognition and TCR antagonism. Here we show that a single amino acid change on the TCR CDR3ß loop can modulate the TCR-antagonistic properties of an altered peptide ligand. Our results highlight the role of the TCR complementarity-determining region 3 loops for controlling the nature of the T cell response to TCR/altered peptide ligand interactions, including those leading to TCR antagonism.
This article has been cited by other articles:
|
|
 |
|
  M. W. Wlodarski, C. O'Keefe, E. C. Howe, A. M. Risitano, A. Rodriguez, I. Warshawsky, T. P. Loughran Jr, and J. P. Maciejewski Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia Blood, October 15, 2005; 106(8): 2769 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Gonzalez, L. J. Carreno, D. Coombs, J. E. Mora, E. Palmieri, B. Goldstein, S. G. Nathenson, and A. M. Kalergis T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell PNAS, March 29, 2005; 102(13): 4824 - 4829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Gakamsky, I. F. Luescher, and I. Pecht T cell receptor-ligand interactions: A conformational preequilibrium or an induced fit PNAS, June 15, 2004; 101(24): 9063 - 9066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Bourcier, D.-G. Lim, Y.-H. Ding, K. J. Smith, K. Wucherpfennig, and D. A. Hafler Conserved CDR3 Regions in T-Cell Receptor (TCR) CD8+ T Cells That Recognize the Tax11-19/HLA-A*0201 Complex in a Subject Infected with Human T-Cell Leukemia Virus Type 1: Relationship of T-Cell Fine Specificity and Major Histocompatibility Complex/Peptide/TCR Crystal Structure J. Virol., October 15, 2001; 75(20): 9836 - 9843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Messaoudi, J. LeMaoult, B. M. Metzner, M. J. Miley, D. H. Fremont, and J. Nikolich-Zugich Functional Evidence That Conserved TCR CDR{{alpha}}3 Loop Docking Governs the Cross-Recognition of Closely Related Peptide:Class I Complexes J. Immunol., July 15, 2001; 167(2): 836 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Thomson, A. M. Kalergis, J. C. Sacchettini, and S. G. Nathenson A Structural Difference Limited to One Residue of the Antigenic Peptide Can Profoundly Alter the Biological Outcome of the TCR-Peptide/MHC Class I Interaction J. Immunol., March 15, 2001; 166(6): 3994 - 3997. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
